PARP1 and breast carcinoma: Finally, the long-term safety association of the anti-PD-1 mAb tilslezumab with pamiparib, a selective PARP-1/2 recently approved in China [309] for the management of germline BRCA mutated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer resistant to previous lines of chemotherapy is currently being evaluated for the treatment of different advanced malignancies [NCT04164199], including ovarian, fallopian tube, peritoneum, pancreas, and breast cancer, in patients who had participated to a previous phase 1a/b study [288,310].